<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39347459</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2633-1055</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Neuroscience insights</Title><ISOAbbreviation>Neurosci Insights</ISOAbbreviation></Journal><ArticleTitle>Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies.</ArticleTitle><Pagination><StartPage>26331055241265668</StartPage><MedlinePgn>26331055241265668</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">26331055241265668</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/26331055241265668</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, emerged in December 2019, sparking a global health crisis. While initially recognized as a respiratory illness, it has become evident that Coronavirus disease 2019 (COVID-19) also affects the central nervous system. This comprehensive review focuses on the neurological manifestations of COVID-19 and its impact on patients with preexisting neurological disorders, particularly those with multiple sclerosis (MS) receiving disease-modifying therapies. Advancements in management, including vaccinations, antiviral therapy, and targeted prophylaxis, have led to a decline in the incidence and severity of COVID-19. Nevertheless, significant complications persist, particularly in patients with advanced MS, who are highly vulnerable to infectious agents like SARS-CoV-2. This review explores the evolving understanding of MS and its association with SARS-CoV-2, encompassing neuroinvasiveness, pathogenesis, disease severity, and outcomes. Research findings reveal substantial neurological implications for some MS patients with COVID-19, with a potential risk of disease relapse and severity. A notable proportion of MS patients experiencing COVID-19 may manifest new symptoms, experience exacerbation of existing symptoms, or encounter both simultaneously, underscoring the diverse neurological effects of the virus. While vaccination and therapeutics have mitigated the overall impact, specific subgroups, especially those on anti-CD20 therapy and with existing disability, remain at higher risk, necessitating ongoing vigilance and tailored care.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hollist</LastName><ForeName>Mary</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0002-4755-7220</Identifier><AffiliationInfo><Affiliation>Atrium Health, Concord, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hollist</LastName><ForeName>Abraham</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Optimal Health Medical Center, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Au</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Loudoun Medical Group, Ashburn, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betts</LastName><ForeName>Colton</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6649-761X</Identifier><AffiliationInfo><Affiliation>Texas A&amp;M University College of Medicine, College Station, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirmani</LastName><ForeName>Maha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Texas A&amp;M University College of Medicine, College Station, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirmani</LastName><ForeName>Maaida</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0009-1123-3487</Identifier><AffiliationInfo><Affiliation>Neuroscience and Experimental Therapeutics, Texas A&amp;M University, College Station, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armour</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Michigan State University, College of Human Medicine, Grand Rapids, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udeh</LastName><ForeName>Mercy C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>University of Tennessee Health Science Center College of Medicine-Chattanooga, Chattanooga, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirmani</LastName><ForeName>Batool F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Texas A&amp;M University College of Medicine, College Station, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, CHI St. Joseph Health, Bryan, TX, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosci Insights</MedlineTA><NlmUniqueID>101760670</NlmUniqueID><ISSNLinking>2633-1055</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">disease-modifying therapies</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>10</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39347459</ArticleId><ArticleId IdType="pmc">PMC11437550</ArticleId><ArticleId IdType="doi">10.1177/26331055241265668</ArticleId><ArticleId IdType="pii">10.1177_26331055241265668</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ward M, Goldman MD. Epidemiology and pathophysiology of multiple sclerosis. Continuum (Minneap Minn). 2022;28:988-1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">35938654</ArticleId></ArticleIdList></Reference><Reference><Citation>Małecka I, Przybek-Skrzypecka J, Kurowska K, Mirowska-Guzel D, Członkowska A. Clinical and laboratory parameters by age for patients diagnosed with multiple sclerosis between 2000 and 2015. Neurol Neurochir Pol. 2021;55:387-393.</Citation><ArticleIdList><ArticleId IdType="pubmed">34355789</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallin MT, Culpepper WJ, Campbell JD, et al.. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92:e1029-e1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6442006</ArticleId><ArticleId IdType="pubmed">30770430</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of SARS-COV-2. Nature. 2021;600:408-418.</Citation><ArticleIdList><ArticleId IdType="pubmed">34880490</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Chen X, He B, et al.. Clinical characteristics of 16 patients with COVID-19 infection outside of Wuhan, China: a retrospective, single-center study. Ann Transl Med. 2020;8:642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290627</ArticleId><ArticleId IdType="pubmed">32566579</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Jin H, Wang M, et al.. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683-690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDougall M, El-Hajj Sleiman J, Beauchemin P, Rangachari M. SARS-CoV-2 and multiple sclerosis: potential for disease exacerbation. Front Immunol. 2022;13:871276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9102605</ArticleId><ArticleId IdType="pubmed">35572514</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ramadan A, Rabab’h O, Shah J, Gharaibeh A. Acute and post-acute neurological complications of COVID-19. Neurol Int. 2021;13:102-119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8006051</ArticleId><ArticleId IdType="pubmed">33803475</ArticleId></ArticleIdList></Reference><Reference><Citation>Mainali S, Darsie ME. Neurologic and neuroscientific evidence in aged COVID-19 patients. Front Aging Neurosci. 2021;13:648662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8021699</ArticleId><ArticleId IdType="pubmed">33833676</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:108427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169933</ArticleId><ArticleId IdType="pubmed">32325252</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWolf S, Laracy JC, Perales MA, Kamboj M, Van Den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022;55:1779-1798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9468314</ArticleId><ArticleId IdType="pubmed">36182669</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019;26:27-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30300457</ArticleId></ArticleIdList></Reference><Reference><Citation>
UpToDate. Pathogenesis and epidemiology of multiple sclerosis. 2023. Accessed August 14, 2023. https://www.uptodate.com/contents/pathogenesis-and-epidemiology-of-multiple-sclerosis?search=multiple%20sclerosis&amp;topicRef=1689&amp;source=see_link</Citation></Reference><Reference><Citation>Rousseau BA, Bhaduri-McIntosh S. Inflammation and Epstein–Barr virus at the crossroads of multiple sclerosis and post-acute sequelae of COVID-19 infection. Viruses. 2023;15:949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10141000</ArticleId><ArticleId IdType="pubmed">37112929</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tafti D, Ehsan M, Xixis KL.
Multiple sclerosis. StatPearls. StatPearls Publishing; 2023. Accessed August 14, 2023. http://www.ncbi.nlm.nih.gov/books/NBK499849/</Citation><ArticleIdList><ArticleId IdType="pubmed">29763024</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry F, Jageka C, Levy PD, Cerghet M, Lisak RP. Review of the COVID-19 risk in multiple sclerosis. J Cell Immunol. 2021;3:68-77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098748</ArticleId><ArticleId IdType="pubmed">33959727</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Lazartigues E. Expression of ACE2 in human neurons supports the neuro-invasive potential of COVID-19 virus. Cell Mol Neurobiol. 2022;42:305-309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334623</ArticleId><ArticleId IdType="pubmed">32623546</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomelli A, Pezzati L, Conti F, et al.. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infections: a cross-sectional study. Clin Infect Dis. 2020;71:889-890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184514</ArticleId><ArticleId IdType="pubmed">32215618</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Wang K, Yu J, et al.. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol. 2021;11:573095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7855591</ArticleId><ArticleId IdType="pubmed">33551947</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97:312-320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10017004</ArticleId><ArticleId IdType="pubmed">32978337</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862.</Citation><ArticleIdList><ArticleId IdType="pubmed">33097561</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020;94:949-952.</Citation><ArticleIdList><ArticleId IdType="pubmed">32241953</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter A, Fox RJ, Newsome SD, et al.. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021;78:699-708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980147</ArticleId><ArticleId IdType="pubmed">33739362</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier UC, Cipian RC, Karimi A, Ramasamy R, Middeldorp JM. Cumulative roles for Epstein-Barr virus, human endogenous retroviruses, and human herpes virus-6 in driving an inflammatory cascade underlying MS pathogenesis. Front Immunol. 2021;12:757302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8592026</ArticleId><ArticleId IdType="pubmed">34790199</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Cortese M, Healy BC, et al.. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375:296-301.</Citation><ArticleIdList><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Waubant E, Lucas R, Mowry E, et al.. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol. 2019;6:1905-1922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764632</ArticleId><ArticleId IdType="pubmed">31392849</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci G, Rinaldi V, Buscarinu MC, et al.. Multiple sclerosis and SARS-CoV-2: has the interplay started? Front Immunol. 2021;12:755333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8503550</ArticleId><ArticleId IdType="pubmed">34646278</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T, Landi D, Liguori C. COVID-19: dealing with a potential risk factor for chronic neurological disorders. J Neurol. 2021;268:1171-1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7450256</ArticleId><ArticleId IdType="pubmed">32852580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziedzic A, Saluk-Bijak J, Miller E, Niemcewicz M, Bijak M. The impact of SARS-CoV-2 infection on the development of neurodegeneration in multiple sclerosis. Int J Mol Sci. 2021;22:1804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7918534</ArticleId><ArticleId IdType="pubmed">33670394</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingues RB, Mendes-Correa MC, De Moura Leite FBV, et al.. First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease. J Neurol. 2020;267:3154-3156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305694</ArticleId><ArticleId IdType="pubmed">32564153</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoso YD, Pacheco FAS, Silveira GL, Oliveira RA, Carvalho VM, Martimbianco ALC. COVID-19 in a temporal relation to the onset of multiple sclerosis. Mult Scler Relat Disord. 2021;50:102863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7902206</ArticleId><ArticleId IdType="pubmed">33662859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanin L, Saraceno G, Panciani PP, et al.. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien). 2020;162:1491-1494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197630</ArticleId><ArticleId IdType="pubmed">32367205</ArticleId></ArticleIdList></Reference><Reference><Citation>Palao M, Fernández-Díaz E, Gracia-Gil J, Romero-Sánchez CM, Díaz-Maroto I, Segura T. Multiple sclerosis following SARS-CoV-2 infection. Mult Scler Relat Disord. 2020;45:102377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340057</ArticleId><ArticleId IdType="pubmed">32698095</ArticleId></ArticleIdList></Reference><Reference><Citation>Khayat-Khoei M, Bhattacharyya S, Katz J, et al.. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol. 2022;269:1093-1106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8417681</ArticleId><ArticleId IdType="pubmed">34480607</ArticleId></ArticleIdList></Reference><Reference><Citation>Havla J, Schultz Y, Zimmermann H, Hohlfeld R, Danek A, Kümpfel T. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. J Neurol. 2022;269:55-58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193159</ArticleId><ArticleId IdType="pubmed">34115170</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori J, Miyazawa K, Nakashima I. Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. J Neuroimmunol. 2021;361:577755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8527738</ArticleId><ArticleId IdType="pubmed">34700047</ArticleId></ArticleIdList></Reference><Reference><Citation>Toljan K, Amin M, Kunchok A, Ontaneda D. New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure. J Neuroimmunol. 2022;362:577785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8656147</ArticleId><ArticleId IdType="pubmed">34922126</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarifkar P, Peinkhofer C, Benros ME, Kondziella D. Frequency of neurological diseases after COVID-19, influenza A/B and bacterial pneumonia. Front Neurol. 2022;13:904796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259944</ArticleId><ArticleId IdType="pubmed">35812108</ArticleId></ArticleIdList></Reference><Reference><Citation>Newsome SD, Cross AH, Fox RJ, et al.. Covid-19 in patients with neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody disease in North America: from the COViMS registry. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8407145</ArticleId><ArticleId IdType="pubmed">34429342</ArticleId></ArticleIdList></Reference><Reference><Citation>
Home. COViMS Registry.
2022. Accessed July 11, 2023. https://www.covims.org</Citation></Reference><Reference><Citation>Klineova S, Harel A, Straus Farber R, et al.. Outcomes of COVID-19 infection in multiple sclerosis and related conditions: one-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC). Mult Scler Relat Disord. 2021;55:103153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286899</ArticleId><ArticleId IdType="pubmed">34392059</ArticleId></ArticleIdList></Reference><Reference><Citation>Garjani A, Middleton RM, Nicholas R, Evangelou N. Recovery from COVID-19 in multiple sclerosis: a prospective and longitudinal cohort study of the United Kingdom multiple sclerosis register. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8631790</ArticleId><ArticleId IdType="pubmed">34848503</ArticleId></ArticleIdList></Reference><Reference><Citation>Muñoz-Jurado A, Escribano BM, Agüera E, Caballero-Villarraso J, Galván A, Túnez I. SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19. J Neurol. 2022;269:4581-4603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9253265</ArticleId><ArticleId IdType="pubmed">35788744</ArticleId></ArticleIdList></Reference><Reference><Citation>
Immune Deficiency Foundation. Update - Evusheld no longer authorized in the U.S. Immune Deficiency Foundation. Published January 26, 2023. Accessed February 24, 2023. https://primaryimmune.org/news/update-astrazenecas-evusheld-authorized-covid-19-preventative-immunocompromised</Citation></Reference><Reference><Citation>Soeroto AY, Yanto TA, Kurniawan A, Hariyanto TI. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2023;33:e2420.</Citation><ArticleIdList><ArticleId IdType="pubmed">36617704</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte WL, Golzarri-Arroyo L. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters. Mult Scler Relat Disord. 2022;63:103905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9123743</ArticleId><ArticleId IdType="pubmed">35661563</ArticleId></ArticleIdList></Reference><Reference><Citation>Reder AT, Centonze D, Naylor ML, et al.. Covid-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs. 2021;35:317-330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980129</ArticleId><ArticleId IdType="pubmed">33743151</ArticleId></ArticleIdList></Reference><Reference><Citation>Habek M, Željko C, Savić Mlakar A, et al.. Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: effects of disease modifying therapies. Mult Scler Relat Disord. 2022;59:103682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824161</ArticleId><ArticleId IdType="pubmed">35158189</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith TE, Madhavan M, Gratch D, et al.. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies. Mult Scler Relat Disord. 2022;60:103735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8915504</ArticleId><ArticleId IdType="pubmed">35398713</ArticleId></ArticleIdList></Reference><Reference><Citation>Novi G, Mikulska M, Briano F, et al.. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord. 2020;42:102120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156942</ArticleId><ArticleId IdType="pubmed">32315980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes R, Whitley L, Fitovski K, et al.. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord. 2021;49:102725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7772086</ArticleId><ArticleId IdType="pubmed">33482590</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson-Yap S, Pirmani A, Kalincik T, et al.. Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 and other risk factors associated with COVID-19 severity. Neurol Neuroimmunol Neuroinflamm. 2022;9:e200021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9423711</ArticleId><ArticleId IdType="pubmed">36038263</ArticleId></ArticleIdList></Reference><Reference><Citation>Spelman T, Forsberg L, McKay K, Glaser A, Hillert J. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: a study of the Swedish multiple sclerosis registry. Mult Scler. 2022;28:1051-1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">34212816</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Bower H, McKay KA, et al.. COVID-19 clinical outcomes and DMT of MS patients and population-based controls. Ann Clin Transl Neurol. 2022;9:1449-1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9463950</ArticleId><ArticleId IdType="pubmed">35993445</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack D, Damian D, Nolting A, Galazka A. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: an update. Mult Scler Relat Disord. 2021;51:102929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997846</ArticleId><ArticleId IdType="pubmed">33813097</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross AH, Delgado S, Habek M, et al.. COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab. Neurol Ther. 2022;11:741-758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8918079</ArticleId><ArticleId IdType="pubmed">35284994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollen C, Bernard J. Multiple sclerosis management during the COVID-19 pandemic. Curr Neurol Neurosci Rep. 2022;22:537-543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9185132</ArticleId><ArticleId IdType="pubmed">35687314</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama T. Causal relationship between immunological responses and adverse reactions following vaccination. Vaccine. 2019;37:366-371.</Citation><ArticleIdList><ArticleId IdType="pubmed">30503656</ArticleId></ArticleIdList></Reference><Reference><Citation>Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014;13:215-224.</Citation><ArticleIdList><ArticleId IdType="pubmed">24514081</ArticleId></ArticleIdList></Reference><Reference><Citation>Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. Lupus. 2009;18:1198-1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">19880568</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC. COVID-19 vaccination. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed August 14, 2023. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html</Citation><ArticleIdList><ArticleId IdType="pubmed">34009769</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs FBS, Mateen FJ, Schmidt H, et al.. Covid-19 vaccination reactogenicity in persons with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579248</ArticleId><ArticleId IdType="pubmed">34753828</ArticleId></ArticleIdList></Reference><Reference><Citation>Allahyari F, Molaee H, Hosseini Nejad J. Covid-19 vaccines and neurological complications: a systematic review. Z Naturforsch C J Biosci. 2022;78:1-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">36087300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail II, Salama S. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol. 2022;362:577765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8577051</ArticleId><ArticleId IdType="pubmed">34839149</ArticleId></ArticleIdList></Reference><Reference><Citation>Alluqmani M. New-onset multiple sclerosis post-COVID-19 vaccination and correlation with possible predictors in a case-control study. Cureus. 2023;15:e36323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10108897</ArticleId><ArticleId IdType="pubmed">37077605</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanou MI, Palaiodimou L, Theodorou A, et al.. Safety of COVID-19 vaccines in multiple sclerosis: a systematic review and meta-analysis. Mult Scler. 2023;29:585-594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9895285</ArticleId><ArticleId IdType="pubmed">36722184</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdani A, Mirmosayyeb O, Ghaffary EM, Hashemi MS, Ghajarzadeh M. COVID-19 vaccines and patients with multiple sclerosis: willingness, unwillingness, and hesitancy: a systematic review and meta-analysis. Neurol Sci. 2022;43:4085-4094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983030</ArticleId><ArticleId IdType="pubmed">35381877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gombolay GY, Dutt M, Tyor W. Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis. Ann Clin Transl Neurol. 2022;9:1321-1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349877</ArticleId><ArticleId IdType="pubmed">35852423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Wang L, Shen L, Tang K. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis. eBioMedicine. 2022;81:104102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9230320</ArticleId><ArticleId IdType="pubmed">35759920</ArticleId></ArticleIdList></Reference><Reference><Citation>König M, Torgauten HM, Tran TT, et al.. Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination. JAMA Neurol. 2022;79:307-309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8787678</ArticleId><ArticleId IdType="pubmed">35072702</ArticleId></ArticleIdList></Reference><Reference><Citation>Januel E, De Seze J, Vermersch P, et al.. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Mult Scler. 2022;28:1155-1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">34931885</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>